TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02734849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001 low dose
Description: 25 mg AK001 will be administered as multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001 high dose
Description: 250 mg AK001 will be administered as multiple doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as multiple doses
Study: NCT02056249

Intervention type: OTHER
Intervention: Norepinephrine Transporter (NET) ligand
Description: Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
Study: NCT03810261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oil-based vitamin D
Description: Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-based vitamin D
Description: Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
Study: NCT03624335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCC
Description: Delayed clamping of the umbilical cord

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 6hours
Description: Blood Test 6hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 6hours
Description: Blood Test 6hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 24hours
Description: Blood Test 24hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 24hours
Description: Blood Test 24hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 48hours
Description: Blood Test 48hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 48hours
Description: Blood Test 48hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 28days
Description: Blood Test 28days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Test 28days
Description: Blood Test 28days
Study: NCT00640588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Arm 1: 600 mg/day, oral telbivudina for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral adefovir
Description: Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
Study: NCT01615770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
Study: NCT03810261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D capsules
Description: Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
Study: NCT03229876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-UCART
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
Study: NCT01594463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: ultrasound examination between week 30+1 weeks to 31+6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: ultrasound examination between 34+1 weeks to 35+6 weeks
Study: NCT03986476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
Study: NCT02484599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized attention training (CAT)
Description: Three sessions of active computerized attention training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham computerized attention training (control condition)
Description: Three sessions of sham computerized attention training.
Study: NCT03432338

Intervention type: OTHER
Intervention: inquiries
Description: Inquires reported to clinician.

Intervention type: OTHER
Intervention: inquiries
Description: Inquires reported to clinician.

Intervention type: OTHER
Intervention: inquiries
Description: Inquires reported to clinician.
Study: NCT02724579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo craniospinal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV or via minibag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV or via minibag
Study: NCT00758368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
Study: NCT02923830

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparinized saline catheter flush
Description: The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline-only catheter flush
Description: The intervention group will have their port catheters flushed with saline only.
Study: NCT00623233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
Study: NCT02414607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elderberry Juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03717025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINI PUNCH GRAFTING
Description: 1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NON CULTURED EPIDERMAL CELL SUSPENSION
Description: 1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal.
Study: NCT02927366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QCC374
Description: 0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching
Description: Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID
Study: NCT04588220

Intervention type: OTHER
Intervention: Obstetric ultrasound and fetal-maternal assessment
Description: melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements

Intervention type: OTHER
Intervention: Obstetric ultrasound and fetal-maternal assessment
Description: melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
Study: NCT04789954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
Study: NCT03278392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo Non-stress task
Description: Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
Study: NCT01548118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 0,5ml
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 0,5ml
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 0.5ml
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 0.5ml
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 1.0ml
Description: Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccine, 1.0ml
Description: Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 1.0ml
Description: Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control, 1.0ml
Description: Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
Study: NCT02974179

Intervention type: BIOLOGICAL
Intervention: Subjects from Study AG-CLI-0206 who received AMG0001
Description: Subjects from Study AG-CLI-0206 who received the study product AMG0001
Study: NCT02474875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)
Study: NCT04789954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
Study: NCT02474875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Patients in experimental groups will receive different educational sessions (contents and duration)
Study: NCT01624792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Dose: 7.0 g/day (= 7 capsules/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Dose: 7.0 g/day (= 7 capsules/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil and placebo
Description: Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
Study: NCT03972735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric interview
Description: PANSS, MADRS, PSP, YMRS
Study: NCT04789954

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa, activated
Description: A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
Study: NCT02388165

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
Description: SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
Study: NCT00510120

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent management training (PMT)
Description: PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative problem solving (CPS)
Description: CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
Study: NCT04210232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS® TORIC II Intraocular Lens (IOL)
Description: Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
Study: NCT02658149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine with NaCl
Description: 50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 0.15 mg Epinephrine are injected as part of the drug cocktail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 4 mg Morphine are injected as part of the drug cocktail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 30 mg morphine are injected as part of the drug cocktail

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 mL 0.5% Ropivicaine are injected as part of the drug cocktail
Study: NCT03880123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food.
Study: NCT04331210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
Study: NCT02458352

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultra low dose non-contrast enhanced CT
Description: Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard dose non-contrast enhanced CT
Description: Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
Study: NCT01381731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diquafosol tetrasodium ophthalmic solution 2%
Description: opthalmic solution 2 drops in each eye QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: opthalmic solution 2 drops in each eye QID
Study: NCT04051489

Intervention type: OTHER
Intervention: Mobile health App - Test
Description: Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection.
Study: NCT01856179

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil
Description: Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil
Description: Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil
Description: Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
Study: NCT01985204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine tablet
Description: Iodine tablets containing 200 ug iodine as potassium iodate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet without iodine
Study: NCT00050570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention to reduce eating disorder risk factors
Study: NCT03508245

Intervention type: OTHER
Group type: OTHER
Intervention: Wearable short wavelength light therapy
Description: Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks